We read with great interest the recent results reported by Ding and colleagues [1] from a trial investigating intravesical positron emission tomography (PET)/magnetic resonance imaging (MRI) using [68Ga]Ga-NOTA-SGC8 targeting PTK7 in non–muscle-invasive bladder cancer (NMIBC). Accurate identification of residual tumor following transurethral resection of bladder tumor (TURBT) remains a major clinical challenge, particularly in the era of bladder-preserving strategies, as repeated resections and multiple intravesical therapies induce extensive inflammatory remodeling of the bladder.
European Urology published a clinical update in Research Highlights on 03 Feb 2026.
The item focuses on Re: Ding Ding, Lei Qian, Di Jin, et al.
Aptamer-based Positron Emission Tomography Imaging Allows Specific Detection of Residual Bladder Cancer: A First-in-Human Study.
Eur Urol 2026;89:93–5.
Review the original article for the full source wording and details.